Wanbury's Patalganga Manufacturing Facility clears US FDA Inspection with Zero Observations

Wanbury Ltd, one of India's fast growing pharmaceutical company having a presence in API global market and domestic branded formulation announced the successful completion of the United States Food & Drug Administration (USFDA) inspection at Patalganga site, Maharashtra. The inspection that started from Monday, June 10, 2024 and completed on Friday, June 14, 2024 was concluded with zero-483 observations.

Mr. Mohan Rayana, Director, Wanbury Ltd. said, "We are pleased to announce the successful completion of the US FDA inspection at our Patalganga site, resulting in zero Form 483 observations. This achievement underscores our commitment to the highest quality and compliance standards at both our API manufacturing sites in Patalganga, Maharashtra, and Tanuku, Andhra Pradesh, both of which are US FDA approved."

Wanbury exports APIs to more than 70 countries including US, Europe, Latin America. The company registered Rs. 575.6 cr in FY24 revenue, 15.2% up YoY.

Shares of Wanbury Limited was last trading in BSE at Rs. 160.35 as compared to the previous close of Rs. 163.55. The total number of shares traded during the day was 14206 in over 551 trades.

The stock hit an intraday high of Rs. 166.70 and intraday low of 160.05. The net turnover during the day was Rs. 2312351.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Patalganga ManufacturingFacility USFDAInspection ZeroObservations